A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 9,99 (+169,27%). A mediana é € 9,08 (+144,74%).
| Comprar |
11 |
| Manter |
3 |
| Vender |
7 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF
MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » Mais em de.investing.com
Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”
Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » Mais em finance.yahoo.com
MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI
MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » Mais em de.investing.com
MannKind: shareholders re-elect nine directors, approve compensation and auditor
At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » Mais em de.investing.com
MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts
MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 89,94 mi | 28,51% |
| Ganho bruto | 69,18 mi | 31,09% |
| Ganho líquido | -20,5 mi | 401,33% |
| EBITDA | -4,73 mi | 131,10% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 1,2 bi |
Número de ações | 321,64 mi |
Máximo/mínimo de 52 semanas | € 5,91 - € 2,02 |
| Dividendos | Não |
Beta | 1,09 |
PER (PE Ratio) | -17,52 |
PEG (PEG Ratio) | 0,17 |
P/VC (PB Ratio) | -35,44 |
P/V (PS Ratio) | 3,21 |
Perfil da empresa
A MannKind Corporation, uma empresa biofarmacêutica, dedica-se ao desenvolvimento e à comercialização de produtos terapêuticos inalados para doenças endócrinas e doenças pulmonares órfãs nos Estados Unidos. Oferece a Afrezza, uma insulina inalada utilizada para melhorar o controlo glicémico em adultos com diabetes. A empresa também promove a Thyquidity junto de endocrinologistas adultos e pediátricos e de outros prestadores de cuidados de saúde, para o tratamento do hipotiroidismo. A empresa tem um contrato de licença e colaboração com a United Therapeutics Corporation. Tem ainda um acordo com a NRx Pharmaceuticals para desenvolver uma formulação em pó seco do ZYESAMI (aviptadil), uma forma sintética do peptídeo intestinal vasoativo humano, que ajuda a proteger as células contra condições inflamatórias. A MannKind Corporation foi constituída em 1991 e tem sede em Westlake Village, Califórnia.
| Nome | MannKind Co. |
| CEO | Michael E. Castagna |
| Sede | Danbury,
ca EUA |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 28/07/2004 |
| Colaboradores | 592 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | MNKD |
Frankfurt | NNFN.F |
Düsseldorf | NNFN.DU |
SIX | NNFN.SW |
München | NNFN.MU |